

Forkortelse	Forklaring
AE	Adverse event
AI	Aromatase inhibitor
ALAT	Alanin aminotransferase
BASP	Basiske fosfataser
Biokemi	ALAT, BASP, Bilirubin, Ca-ion
CEF	Cyclofosfamid, epirubicin og fluorouracil
CR	Komplet respons
CMF	Cyclofosfamid, methotrexat og fluorouracil
CRF	Case report form
CTC	Common toxicity criteria
DBCG	Danish Breast Cancer Cooperative Group
DDFS	Distant disease-free survival
DFS	Disease-free survival
Doc	Docetaxel
EBCTCG	Early Breast Cancer Trialist' Collaborative Group
EC	Epirubicin og cyklofosfamid
ER	Estrogen receptor
FISH	Fluorescence in situ hybridisation
GCP	Good Clinical Practice
HER2	Human epidermal vækstfaktor receptor 2
IDFS	Invasive disease-free survival
IHC	Immunohistochemistry
ITT	Intention to treat
MTA	Micro tissue array
OS	Overall survival
pCR	Komplet patologisk respons
PgR	Progesteron receptor
PR	Partiel respons
RCB score	Residual cancer burden score
RECIST	Response Evaluation Criteria In Solid Tumours
SAE	Serious adverse event
SN	Sentinel node
SUSAR	Suspected unexpected serious adverse reaction
TOP2A	Topoisomerase II alpha genet
Topo II	Topoisomerase II alpha enzymet